Apogee Therapeutics to Present at Stifel 2025 Virtual Immunology and Inflammation Forum

Apogee Therapeutics announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum, where management will participate in a fireside chat on September 16, 2025. The company's most advanced program, APG777, is being developed for the treatment of Atopic Dermatitis. Apogee's pipeline includes four validated targets and aims to deliver value and benefit to patients underserved by today's standard of care.

Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced its participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T. [1]

The fireside chat will provide investors and interested parties with an opportunity to hear directly from Apogee's leadership about the company's progress and future plans. A live and archived webcast of the event will be available via the News & Events page in the Investors section of Apogee Therapeutics' website.

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for various indications, including Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD). The company's most advanced program, APG777, is being initially developed for the treatment of AD, one of the largest and least penetrated markets in the immune and inflammatory (I&I) space. Apogee's pipeline includes four validated targets, with the aim of delivering best-in-class profiles through monotherapies and combinations of its novel antibodies. [1]

The company's approach involves targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. By doing so, Apogee Therapeutics seeks to provide meaningful benefits to patients currently underserved by existing therapies. [1]

For more information about Apogee Therapeutics and its upcoming events, please visit their website at [https://apogeetherapeutics.com](https://apogeetherapeutics.com). Investor inquiries can be directed to Noel Kurdi, VP, Investor Relations, at [noel.kurdi@apogeetherapeutics.com](mailto:noel.kurdi@apogeetherapeutics.com). [1]

References:
[1] https://www.stocktitan.net/news/APGE/apogee-therapeutics-to-participate-at-the-stifel-2025-virtual-67s3kws5qpr5.html